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Background:Controversy persists as towhether all calf vein thrombi shouldbe treatedwith anticoagulationorobservedwithduplex
surveillance. We performed a systematic review of the literature to assess whether data could support either approach, followed by
examinationof its natural history by stratifying results according to early clot propagation, pulmonary emboli (PE), recurrence, and
postthrombotic syndrome (PTS).
Methods:Atotalof1513articleswere reviewedthatwerepublished fromJanuary1975toAugust2010usingcomputerizeddatabase
searches of PubMed, Cochrane Controlled Trials Register, and extensive cross-references. English-language studies specifically
examining calf deep vein thrombosis (C-DVT) defined as axial and/or muscular veins of the calf, not involving the popliteal vein,
were included. Papers were independently reviewed by two investigators (E.M., F.L.) and quality graded based on nine methodo-
logic standards reporting on four outcome parameters.
Results:Of the 1513 citations reviewed, 31 relevant papersmeeting predefined criteria were found: six randomized controlled trials
(RCT) and 25 observational cohort studies or case series. There was a single RCT directly comparing anticoagulation with no
anticoagulation with compression and duplex surveillance, and they found no difference in propagation, PE, or bleeding in a
low-risk population. Based on two studies of moderately strong methodology, C-DVT propagation was reduced with anticoagu-
lation. When treatment was unassigned, moderately strong evidence suggested that about 15% propagate to the popliteal vein or
higher.However, basedonnonrandomizeddata butwithmoderate tohighquality (levelA andB studies), propagation topopliteal
or higher was 8% in those with no anticoagulation treated with surveillance only. Propagation involving adjacent calf veins but
remaining in the calf occured in up to one-half of all thosewho propagate.Major bleedingwas an intended endpoint in threeRCTs
andwas reported as 0% to6%,with a trend toward lower bleeding risk inmore recent studies. PEduring surveillance in studieswith
unassigned treatment was strikingly lower than the historical reports of PE recorded at presentation, emphasizing the distinction
thatmustbemadebetweenthe twoentities.Recurrence inC-DVTis lower thanthighDVT,anddata suggest that in low-riskgroups
with transient risk factors, 6 weeks of anticoagulation may be sufficient, as opposed to 12 weeks. Studies of PTS reported that
patients with C-DVThad fewer symptoms than their thighDVT counterparts. Approximately one out of 10 showed symptoms of
CEAP Class 4 to 6; however, C5 or C6 with healed or active ulceration were not commonly encountered.
Conclusions:No study of strongmethodology could be found to resolve the controversy of optimal treatment ofC-DVT.Given the
risks of propagation, PE, and recurrence, the option of doing nothing should be considered unacceptable. In the absence of strong
evidence to support anticoagulation over imaging surveillance with selective anticoagulation, either method of managing calf DVT
must remain as current acceptable standards. (J Vasc Surg 2012;55:550-61.)
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tWhile anticoagulation remains the mainstay treatment
of proximal limb deep venous thrombosis, treatment of calf
deep vein thrombosis (C-DVT) that does not involve the
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550opliteal vein remains controversial. On the one hand, the
ignificance of C-DVT is clinically important because it can
otentially propagate, result in pulmonary emboli (PE)
nd/or death, recur, and/or lead to postthrombotic syn-
rome (PTS). On the other hand, anticoagulation for all
s challenged by the potentially undesirable effects of
ajor bleeding, including death, burden of treatment,
nd increased utilization of costly resources. This is in
tark contrast to anticoagulation for proximal thigh
VT, which is not disputed and universally accepted as
tandard of care.
Guidelines for treatment of C-DVT are lacking and do
ot address the current practice of C-DVTmanagement. In
n electronic poll of attendees taken at the 2009 American
enous Forum and the 2009 American College of Phlebol-
gy, there were approximately equal numbers of votes for
nd against anticoagulation for C-DVT. In 2008, the
merican College of Chest Physicians (ACCP)1 published
heir recommendation specifically for first unprovoked C-
VT, and assigned it a Grade 2B with suggestion that
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Volume 55, Number 2 Masuda et al 551duration of anticoagulation be limited to 3 months as
opposed to indefinite therapy. Although treatment of C-
DVT was implied, there were no direct recommendations
addressing C-DVT, particularly those with transient or
reversible risk factors.
Because of this controversy, we undertook this review
to identify pertinent evidence in either supporting or not
supporting anticoagulation for C-DVT and examine four
features of C-DVT – clot propagation, PE, recurrence, and
PTS – which may provide further evidence of the natural
history of calf vein thrombi and a foundation for future
evidence-based research.
METHODS
Studies selected for review were required to fulfill the
following inclusion criteria. For many of these questions,
randomized controlled trials (RCTs) did not provide suffi-
cient data and were not the appropriate design to address
the clinical question raised. As a result, observational stud-
ies with or without internal or historic controls and case
series with explicit details of one or more of the four
parameters studied were included in this analysis. The
literature was examined by searching using keywords: “calf
vein thrombosis,” “calf DVT,” “isolated calf DVT,” “distal
DVT,” and “lower limb DVT.” The search was limited to
English language papers published between January 1975
and August 2010 using computerized database searches of
PubMed, Cochrane Controlled Trials Register, and exten-
sive cross-references.
Inclusion criteria
1. Calf vein thrombi are defined by involvement of the
axial veins (peroneal, posterior tibial, and/or anterior
tibial veins) and/or muscular calf veins (soleal or gas-
trocnemius veins), not involving the popliteal or higher
veins.
2. Diagnosis must include imaging studies of the entire
leg, including the calf.
3. To examine the natural history of C-DVT, the specific
aim(s) of each study should include one or more of the
following: propagation of C-DVT, PE during surveil-
lance, DVT recurrence, and/or PTS.
Exclusion criteria
1. Since the purpose to this review was to report the
outcome of treatment and the natural history of calf vein
thrombi, studies reporting only the prevalence of C-
DVT or PE were not included in the analysis but may be
cited in the discussion.
2. Studies with the arbitrary sample size of 20 or less were
excluded.
3. Any study reporting early outcome with 40% or more
subjects lost to follow-up from the original study group
were excluded. crading of methodology
Studies that qualified for review were graded based on
ethodology, utilizing a modified rating system published
y Philbrick and Becker.2 Since most of the studies were
ot designed to study the natural history of C-DVT, if
ompliance with the standards were not achieved, this did
ot infer that the study quality was poor or inadequate. The
tandards (see Appendix) were used to rate the overall
uality of the study and provide an estimate for the strength
f evidence that can be assigned to each of four outcomes
easured.
rading strength of evidence
Papers were graded based on whether they met any or
ll of nine standards. Papers were rated “strong” or as-
igned a grade “A” in methodology if eight or more stan-
ards were met, moderately strong or grade “B” if they met
total of six to seven standards, and all others were rated as
eak or grade “C.”
ESULTS
One thousand, five hundred thirteen citations were
eviewed (Fig 1), and, after exclusion based on previously
tated criteria, 31 were included for analysis.
Studies not included in analysis. Several studies did
ot meet the inclusion criteria because C-DVT cases in-
luded popliteal DVT and separate analysis was not
ade,3,4 C-DVT was not distinguished from popliteal
VT,5 “distal DVT” was not defined,6,7 sample size was
ess than 20,8-11 complete imaging studies of the entire leg,
ncluding calf were lacking,12-14 results were not analyzed
eparately from proximal DVT,15,16 details of the C-DVT
roup were not specified,17 reports described prevalence or
ncidence of disease, without surveillance data,5,18-21 and
0% or more of the initial study group were excluded from
nalysis because of lack of follow-up in the process of
easuring early outcome.22
Randomized controlled trials. Six RCTs (Table I)
ere identified with five of the six designed to study drug
oses, routes, and duration of therapy of C-DVT.
Rate of propagation. There were only two studies of
igh quality27,28 (Grade A) examining the rate of DVT
ropagation (Table II). In an RCT by Schwarz et al,28 the
ate of propagation was not significantly different between
hose who received therapeutic Nadroparin for 10 days
ompared with compression therapy alone (3.7% vs 3.8%;
NS). In the low risk group of 107 patients, only 4.67%
ad active cancer, and 20% to 47% had a transient risk factor
uch as trauma or surgery. When calculated for only pro-
ression of thrombi to the popliteal vein or higher, both
roups had the same rate of 1.9%. They concluded their
ata did not show superiority of short-term anticoagulation
ver compression for muscular calf vein thrombi (MCVT)
n a low-risk population. Ferrara and colleagues27 exam-
ned the optimal duration of anticoagulation in one
ersus two or more vein involvement. They found that
lot propagation was equivalent in C-DVT limited to
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February 2012552 Masuda et alone vein, whether treated for 6 or 12 weeks; however,
the rate of propagation was significantly worse if two or
more calf vein thrombi were treated for 6 weeks versus 12
weeks (35.5% vs 9.7%; P  .001), advocating the longer
treatment for two or more veins.
Of the remaining 16 studies, 11 were rated “moder-
ately strong” in methodology and reported the risk of
propagation to the popliteal vein or higher in 2.9% to
17.9%. Any propagation, including thrombus extension
within the calf that involved adjacent calf veins and clot
ascending up into the popliteal vein, was reported by Lohr
et al30 of 32%, with a second report32 of 28%. When
analyzed for propagation only to the popliteal or above, the
number reduced to one-half the initial estimate and is
reported at 14.7% and 10.9%, respectively.30,32 Similarly,
Labropoulos38 found propagation to adjacent uninvolved
calf veins and popliteal veins in 27%, but only 13% propa-
gated to the popliteal.
In two studies of no anticoagulation, the risk of propaga-
tion to the popliteal level was 3% to 4.6%.39,42 MacDonald et
al39 found any propagation in 16.3%, with only 3% propaga-
Fig 1. Summary of literature search and derivation of studies for
analysis.tion to the popliteal or higher in MCVT. Based on the low 5ate of serious propagation, they concluded that MCVT can
e observed with serial duplex surveillance.
In Fig 2 and Table III, analysis of cases receiving no
nticoagulation provided some insight into the possible
atural history of C-DVT. The pooled data from Grade A
nd B studies without anticoagulation showed that with
scent up the limb, the rate of propagation above the calf
iminished. However, the data must be interpreted with
aution as there may have been selection bias with only one
tudy being an RCT.
Moderately strong evidence suggests that anticoagula-
ion reduces propagation as indicated by one observational
ohort study by Schwarz et al,37 of MVCT. They found
hat 25% propagated into any vein, which was defined as
naffected axial calf veins or popliteal veins in the cohort
ith observation, compression stockings, and duplex sur-
eillance (confirmed by direct correspondence with primary
uthor), whereas the group receiving low-molecular-
eight heparin for 10 days showed no propagation. De-
pite the nonrandomized design and possibility of bias,
esults suggest that clot propagation in the calf, including
djacent veins without extension into the popliteal, can be
educed with a short course of anticoagulation.
While these studies suggest benefits of anticoagulation,
isks of bleeding pose an undesirable effect that must be
onsidered in weighing the benefits against risks. Three of
he six randomized studies measured bleeding as an out-
ome (Table I), ranging from 0% to 6%.24,26,28 Lager-
tedt25 described two cases of major bleeds, including one
ach of retroperitoneal hematoma, and calf hematoma with
ompartment syndrome; however, bleeding was not one of
heir endpoints.
PE during surveillance. There were 13 studies that
eported PE during surveillance (Table IV) and of these,
hree of the 11 were graded “moderately strong to strong”
s they provided predetermined repeat lung ventilation/
erfusion (V/Q) scans, which allowed identification of
oth asymptomatic and symptomatic emboli. Hull,23
entley,24 and Partsch43 found that in patients treated with
nticoagulation, PE during surveillance was 0% to 6.2%.
he largest report of 238 patients by Partsch43 demon-
trated 3.4% new PE in those with V/Q scan surveillance at
ay 1 and day 10, the majority of which were asymptom-
tic, and only a few developed mild symptoms. The limita-
ion, however, was the study’s short follow-up of 10 days.
n three studies with cohorts that did not receive anticoag-
lation with follow-up of 3 months or more,28,37,42 the
ncidence of symptomatic PE was 0% to 1.5%. There was
ne death from a pulmonary embolus during surveillance
eported by O’Shaughnessy,34 in which case the DVT
ropagated first to the popliteal vein; however, no details
ere given with respect to whether the patient was receiv-
ng anticoagulation or undergoing surveillance.
Recurrence. There were no strong studies reporting
ecurrence between anticoagulation and surveillance. The
tudy that comes closest is the RCT by Lagerstedt,25 in
hich the entire group was treated with anticoagulation for
days, then randomized to warfarin or no warfarin for at
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Volume 55, Number 2 Masuda et al 553least 3 months. The recurrence was 29% in 90 days, all of
which occurred in the cohort not receiving warfarin for 3
months as compared with no recurrence in the group
receiving warfarin (P .01). In Table V, the difference in
outcomeofC-DVTandproximalDVTwere reported and the
study by Hull23 was rated strong in methodology in which
low-dose heparin treatment of C-DVT was associated with a
low recurrence as opposed to a higher recurrence with proxi-
mal DVT (0% vs 47%; P .001). In the Duree Optimale du
Traitement Antivitamines K (DOTAVK) trial consisting of
197 calf DVT patients, Pinede and colleagues26 found overall
recurrence was lower for C-DVT than proximal DVT or PE
(2.6% vs 8.4%, respectively), and their results supported a
shorter duration of anticoagulation of 6 weeks as opposed to
12 weeks of anticoagulation for C-DVT. In addition, they
were one of the few studies to report a higher risk of recur-
rence with cancer, idiopathic DVT, and permanent risk
factors.
PTS. Studies of PTS (Table VI) included a longitudi-
nal study by Meissner33 who reported 23% with symptoms
limited to pain and swelling; however, no hyperpigmenta-
Table I. Randomized controlled trials of C-DVT
Author
Type of
study Aim
Hull (1979)23 RCT Compared warfarin with low-
dose heparin subcutaneous
for 6 weeks; all preceded by
heparin IV for 14 days.
Rec
Bentley (1980)24 RCT Compared heparin IV vs
subcutaneous for 7 days,
measuring safety and efficacy
Prox
d
b
Lagerstedt
(1985)25
RCT All received heparin IV for 5
days, then compared
warfarin vs no warfarin
Rec
Pinede DOTAVK
study (2001)26
RCT Compared oral anticoagulation
6 vs 12 weeks for subgroup
C-DVT; all received initial
subcutaneous or IV heparin
Rec
Ferrara (2006)27 RCT Compared 6-week with 12-
week anticoagulation in
single vs two C-DVT
Prox
Schwarz (2010)28 RCT LMWH 10 days vs
compression treatment plus
surveillance
Prox
b
re
C-DVT, Calf deep vein thrombosis; DVT, deep vein thrombosis; IV, intrave
emboli; RCT, randomized controlled trial.tion or ulceration were found at 1 year. Compared with aontrols, McLaffety51 found that at 3.4 years, few showed
igns of significant venous symptoms. With follow-up ex-
ended to 5 years, Asbeutah53 reported 11% with CEAP
lass 4 to 6 findings. In a unique study of asymptomatic
-DVT, Rosfors and colleagues54 reported a low incidence
f PTS symptoms of 4% at 5 years, and amild degree of PTS
y Villalta scoring. Overall venous ulceration was not com-
only encountered in follow-up.
ISCUSSION
The studies presented in this review confirm the lack
f scientific evidence substantiating either anticoagula-
ion or observation with surveillance testing as optimal
reatment for C-DVT. Although three national societies
r international consensus groups (ACCP, Australian
ociety of Thrombosis and Haemostasis, and the British
VT consensus group) have recommended anticoagula-
ion for C-DVT, observation and compression therapy
ith duplex surveillance remains a commonly practiced
dpoint Findings/comments: % Major bleeding
ce Subgroup analysis of C-DVT
patients showed no
difference between either
therapy.
NR
extension, PE
surveillance,
g
Subcutaneous heparin
resulted in lower
propagation rates than IV
heparin. No difference
found with PE rates.
6/100 (6%)
ce Recurrences within 90 days
was lower in group
receiving warfarin for at
least 3 months, as opposed
to no warfarin.
2/51 (4%)
ce, bleeding Subgroup analysis of C-DVT
patients showed 6-weeks
treatment was sufficient
and no difference in
recurrence from 12 weeks.
C-DVT lower risk for
recurrence than proximal
DVT.
4/197 (2%)
extension C-DVT involving single vein,
6-week treatment was
sufficient. Twelve-week
treatment was better for
C-DVT involving two or
more veins, in postsurgical,
“low-risk” group.
0
extension, PE
g,
ization
In low-risk population, did
not show superiority of
LMWH over compression
therapy in calf muscle
DVT.
0
LMWH, low-molecular-weight heparin; NR, not reported; PE, pulmonaryEn
urren
imal
uring
leedin
urren
urren
imal
imal
leedin
canal
nous;pproach. In fact, the single RCT published to date
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vealed no statistically significant difference between 10
days of low molecular weight heparin and compression
therapy for 3 months.
The current review suggests the overall propagation
rate to the popliteal or femoral vein is approximately 15% in
reports with unassigned treatment; however, it may be as
low as 2% in low-risk groups with transient risk factors and
Table II. Calf vein thrombosis propagation
Author (year)
No. patients
(limbs)
Surveillance
methods
Bentley (1980)24 100 Venography Hep
w
Hep
w
Lagerstedt (1985)25 51 99TC plasmin
supplemented by
venography
Hep
Hep
Kakkar and
Lawrence
(1985)29
98 Venogram Hep
m
Lohr (1991)30 75 DUS Mix
Solis (1992)31 42 (50) DUS in 32 Anti
No a
Lohr (1995)32 192 DUS Anti
No a
Meissner (1997)33 29 (37) DUS Mix
O’Shaughnessy
(1997)34
50 DUS Mix
Masuda (1998)35 49 DUS Anti
No a
Kazmers (1999)36 71 DUS Mix
Schwarz (2001)37 84 Venous compress
ultrasound
LMW
Obs
Labropoulos
(2002)38
48 (52) DUS Anti
No a
MacDonald
(2003)39
135 DUS No a
Ferrara (2006)27 192 DUS Anti
ca
w
Anti
ve
Wang, CJ(2007)40 160 Venogram 5-7
days, then 3
months
Mix
do
Parisi TICT
(2009)41
171 DUS Anti
LM
da
do
Palareti(2010)42 65 DUS No a
Schwarz (2010)28 107 DUS Ran
A
LM
No a
co
pl
DUS, Duplex ultrasound; LMVH, low-molecular-weight heparin.
aMixed: outcomes not reported by treatment.
bAny propagation defined as propagation in the same vein, adjacent uninvo
cShort follow-up of 7 days.
dNumber represents both the Anticoagulation and No Anticoagulation grocalf muscle vein thrombi.27 In a pooled analysis of nonran- womized studies of level A and B quality, the estimated rate
f propagation to the popliteal or higher in those treated by
urveillance only and no anticoagulation is 8% (Fig 2). This
iscrepancy between propagation rates underscores the
eed for controlled studies specifically analyzing the effects
f surveillance or treatment. Unlike the report by Philbrick
nd Becker,2 who reported no fatal PE, we found one single
eport of a fatal PE while under study,33 but no mention
eatment
% Any
propagationb
% Propagation
popliteal or higher Rating
ubcutaneous 
 6 weeks
— 0 Cc
ntravenous 
 6 weeks
2%
no warfarin — 17.9% B
warfarin 0
coumadin 3 — 10% B
32% 14.7% C
lation — 23% C
agulation 8%
lation 13% 10.9%d Bagulation 22.4%
— 16% B
— 15% B
lation — 0 B
agulation 7.7%
— 15.5% C
10 days 0 B
on, stockings 25%
lation 10.5% 13%d Bagulation 17.2%
agulation 16.3% 3% B
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Volume 55, Number 2 Masuda et al 555anticoagulation. Aside from this single event, the findings
from this review revealed few major adverse events early on
with observation, compression therapy, and duplex surveil-
lance and would support this as an option.
What role does anticoagulation have in reducing the
propagation rate? Two strong to moderately strong studies
reported that anticoagulation reduced propagation rate.
Lagerstedt25 studied the effects of treating 51 cases of
C-DVTwith 5 days of intravenous heparin and randomized
them to receive warfarin for 3 months or no warfarin. They
found a statistically significant number of patients with
warfarin resulted in reduction in recurrence, proximal ex-
tension, and PE when compared with no warfarin. How-
ever, the diagnosis of DVT and follow-up studies relied on
the 99 m Technesium plasmin test, which currently is not
used in practice. Schwart et al37 found, in a nonrandomized
observational cohort study of 84 patients, that those not
receiving anticoagulation developed a statistically signifi-
8%
4%
4%
6%
8%
10%
(%
)
0%
2%
calf vein* popli
Pe
rc
en
t 
Level of Propaga
Fig 2. Level of propagation with no anticoagulation. D
DVT propagated within the axial calf veins or muscular
Table III. Data for level of propagation with no
anticoagulation, in grade A and B studies within 3
months follow-up
Author Calf Popliteal Femoral
Pulmonary
emboli
Total
cases
Palareti42 1 3a 1 65
MacDonald39 18 4 135
Schwarz28 1 1 53
Lohr32 17 11 10 169
Masuda35 1 1 26
Labropoulos38 4b 1 29
Total 477
aPalareti: three cases of “proximal deep vein thrombosis.”
bLabropoulos: four cases of “popliteal or higher.”cant higher rate of progression from muscle calf vein nhrombosis to deep or axial calf vein thrombi and popliteal
VT. Contrary to their initial report, the same authors
ublished their RCT28 nine years later comparing low
olecular weight heparin for 10 days with compression and
ound no statistical significance in propagation, PE, bleed-
ng, and death.
The outcome of this review would support anticoagu-
ation if a higher value was placed on preventing clot
ropagation and recurrence and a lower value was placed
n the burden of treatment, cost for intervention, and if the
isk of major bleeding was deemed acceptable. Notably, the
eport of major bleeding from the six RCTs ranged from 0%
o 6%, with bleeding risk decreasing over time. This is not
urprising since improved methods of anticoagulation with
MWH heparins and other alternatives to unfractionated
eparin have evolved favorably. In the RCT by Schwarz,28
he risk of bleeding was the same in the anticoagulation and
onanticoagulation groups, although the study may have
een under-powered to detect differences in major bleed-
ng, given the limited sample size of 107.
In many ways, C-DVT differs from proximal DVT and
xplains differences in approaches. C-DVT propagates less
ften than proximal DVT,41 has a lower PE risk,18 is more
ikely asymptomatic,54,55 and does not appear to lead to
TS as often.33,52 Further, recurrence rates are reported to
e lower with C-DVT as opposed to proximal DVT when
reated with anticoagulation.17,26
For those who choose a selective approach to anticoag-
lation, identifying the high-risk patient is critical. Three
tudies36,37,39 found that malignancy was associated with
ncreased risk of propagation and advocate anticoagulation
or this high-risk group. MacDonald39 reported that ma-
ignancy was associated with propagation, whereas tran-
ient risk factors such as recent surgery and trauma were
3%
0.40%
femoral PE
 from the Original Calf DVT
eep vein thrombosis; PE, pulmonary embolism. *Calfteal
on
VT, Dot; prior venous disease, cardiac disease, and hypercoagu-
O
m
b
a
D
r
t
d
a
l
b
r
s
g
f
a
w
m
I
fi
n
n
t
fi
t
t
s
t
i
t
JOURNAL OF VASCULAR SURGERY
February 2012556 Masuda et allable states were also not associated. In a large series re-
ported by Lohr and colleagues32 of 192 patients predomi-
nantly consisting of patients with transient risk factors such
as surgery, trauma, and estrogen use, predictors of propa-
gation could not be identified; however, the group was
comprised of 10% malignancy, and idiopathic DVT was
not analyzed. In the DOTAVK trial of 197 C-DVT cases,
Pinede26 found a higher rate of recurrence with cancer,
idiopathic DVT, and permanent risk factors.
Unprovoked or idiopathic DVT may be a significant
risk factor for C-DVT propagation. In the Treatment of
Isolated Calf Thrombosis (TICT) trail, Parisi et al41 found
clot extension occurred despite anticoagulation in 2.9%,
and the association between complication of DVT and
unprovoked C-DVT was significant (P .005). Idiopathic
C-DVT was not analyzed in most studies in this review, but
is a known important risk factor for recurrence in proximal
and distal DVT,17,58 and future studies should account for
this variable.
Bilateral leg C-DVTmay be a marker of worse progno-
sis and is associated with increased recurrence,46 increased
mortality,47 and increased association with malignancy.47
Galanaud48 found an increased association of bilateral C-
DVT and mortality than those with unilateral C-DVT
(17.4% vs 3.0%; P .008) and an association of bilateral leg
DVT with active cancer.
Multiple calf vein involvement and initial clot burden
may be associated with increased propagation.27,45 In an
RCT by Ferrara,27 propagation and recurrence was signif-
icantly higher in two calf vein thrombi as opposed to a
single vein clot. Gillet and colleagues45 reported increased
risk for propagation and risk of PE with increased initial calf
Table IV. Pulmonary emboli during surveillance
Author
No. of patients
(limbs) Surveillance me
Hull (1979)23 32 V/Q scan at 2
6 weeks
Bentley (1980)24 32 V/Q scans at 1
7 days
Solis (1992)31 42 (50) Clinicalb
O’Shaughnessy (1997)34 50 Clinicalb
Meissner (1997)33 29 (37) Clinicalb
Masuda (1998)35 49 Clinicalb
Partsch (2001)43 238 V/Q scans at 1
10 days
Schwartz (2001)37 84 Clinicalb
Labropoulos (2002)38 48 (52) Clinicalb
Wang, CJ(2003)44 48 Clinicalb
Gillet (2007)45 128 Clinicalb
Palareti (2010)42 65 Clinicalb
Schwarz (2010)28 107 Clinicalb
aMixed: outcomes not reported by treatment.
bClinical identification of symptomatic pulmonary emboli, with diagno
tomography angiogram of the chest when clinically suspected.
c15.5% of series included popliteal vein deep vein thrombosis.vein diameters 8 mm, and, according to a report by thgi,19 thrombus distending the vein to a diameter 7
m was associated with a greater chance for thromboem-
olic complications. Thrombophilias, especially hereditary,
nd those with positive family history are known risks for
VT complications.56 Due to small numbers and limited
eports examining thrombophilia in C-DVT cases, its rela-
ionship with calf vein thrombi complications could not be
etermined by this review. However, other interesting
spects of recurrence under investigation include d-dimer
evels57 and residual thrombosis on ultrasonography,58
oth of which may prove to be important predictors of
ecurrence and guide duration of anticoagulation.
Should those with C-DVT and low risk be offered a
horter duration of anticoagulation? Two RCTs26,27 sug-
est that 6 weeks is adequate length of anticoagulation and
ound that extending treatment to 12 weeks did not prove
dvantageous. Ferrara27 reports that for single C-DVT, 6
eeks of anticoagulation would suffice, and only if two or
ore calf veins were involved would 12 weeks be needed.
n the DOVTAK trial, Pinede et al26 likewise reported their
ndings where extending anticoagulation to 12 weeks did
ot confer an advantage over a 6-week regimen. Although
ot included in this analysis, the Duration of Anticoagula-
ion (DURAC) trial17 found, in a subgroup analysis of
rst-time distal DVT patients with 2-year follow up, that
here was no benefit in extending duration of anticoagula-
ion to 6 months as opposed to 6 weeks, supporting a
horter duration of treatment. These findings are in con-
rast to the report by Kearon and colleagues15 who found
n a mixed group of proximal and distal DVT, those with
ransient risk factors showed higher recurrences when
Type of treatment
Results: % pulmonary
emboli
Rating of
methodology
Anticoagulation 0 A
Anticoagulation 6.2% A
Mixeda 0 C
Mixeda 2% C
Mixeda 3% C
Mixeda 0 C
Anticoagulation 3.4% B
Anticoagulation 0 C
No anticoagulation 0
Mixeda 2% C
Mixeda 0 C
Anticoagulation 4.7%c C
No anticoagulation 1.5% C
Anticoagulation 0 B
No anticoagulation 0
firmed by V/Q scanning, pulmonary angiography, and/or computedthod
and
and
and
sis conreatment was reduced to 1 month as opposed to 3
l
T
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t
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p
p
t
c
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t
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EV tr
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Volume 55, Number 2 Masuda et al 557months and recommended against shortening the dura-
tion of anticoagulation.
Clot lysis in C-DVT appears to be lysed in one-half of
patients by the 3rd month, and by the 6th month, all have
lysed. This is according to duplex surveillance stud-
ies.28,35,39,45,52Whether this finding influences duration of
anticoagulation remains to be further examined.
PE during surveillance of C-DVT with serial pulmo-
nary V/Q scans of both asymptomatic and symptomatic PE
up to 10 days after initial diagnosis is 3.4%,43 and the
majority appear asymptomatic. From a methodologic
standpoint, PE at presentation must be distinguished from
PE during surveillance. In contrast to the low incidence of
PE during surveillance, reports of PE at presenta-
tion33,34,36,43,46 are higher and range from 5% to 56%, with
the largest series by Partsch,43 who reported 35.1% with PE
at presentation. In a registry of 895 distal DVT, Senturier et
al47 reported PE at presentation in 29% with single-leg
distal DVT, and 45% in bilateral C-DVT. These strikingly
large numbers of PE identified in the presence of C-DVT
Table V. Recurrence
Author
No. of
patients
(Limbs)
Duration of
follow-up Surveillance testing
Hull (1979)23 32 6 weeks Impedance
plethysmography,
125 I-fibrinogen,
and venography
Lagerstedt (1985)25 51 1 year 99Tc plasmin and
venography
O’Shaughnessy
(1997)34
50 Up to 1
year
DUS
Astermark (1998)46 126 2 years Venography
Pinede (2001)26 197 12 months Clinical
Wang (2003)44 48 3-4 years Venography in 33
Senturier (registry)
(2005)47
895 2 years Clinical
Gillet (2007)45 128 26.7
months
DUS
Parisi TICT
(2009)41
171 3 months DUS
Galanaud,b
OPTIMEV
(2010)48
725 3 months Clinical
C-DVT, Calf deep vein thrombosis; DUS, duplex ultrasound; DVT, deep ve
aMixed: outcomes not reported by treatment.
bFor previous publication by same authors, see Galanaud (2009)49; OPTIMmay be the result of dislodgement of a more proximal clot Ieaving residual thrombus in the calf. Browse and
homas59 showed that in one out of three cases of PE, the
eg venograms were negative for DVT, and concluded that
he thrombi in the legs may have left the leg entirely.
arterr et al60 reported a case of a patient with multiple PE
nd correlated the finding with disappearance of a below-
nee thrombus, providing evidence that embolization can
esult in the absence of clot in the limb. Multiple stud-
es23,61-63 suggest that most fatal PE occur as a result of
rior proximal extension and lack of treatment, as op-
osed to clot arising directly from the calf veins. Because
here is no way of determining whether a more proximal
lot had detached from the leg above the C-DVT, it is
ifficult to estimate the true risk of PE based on the
nitial presentation.
Adding to the confusion of the association of C-DVT
nd PE is the fact that many PE at presentation are asymp-
omatic. In a study designed to examine the prevalence of
E in those with C-DVT, Kistner and Moreno-Cabral18
ound PE at presentation in 33%, of which 45% were silent.
determined
peat studies Treatment % Recurrence
Rating of
methodology
3 and 6
eeks
Heparin intravenous
then warfarin 6
weeks
0
0
A
Heparin
subcutaneous  6
weeks
y 5, 14, and
0 and 90
ays
Heparin intravenous
plus warfarin
4.3% B
Heparin intravenous
plus no warfarin
32%
1 week, 1
onth, 6
onths, and
year.
Mixeda 14% B
ne Heparin  VKA 6
weeks
8.7% C
ne Heparin  VKA 12
weeks
3.4% B
Heparin  VKA 6
weeks
2%
Not reported 0 C
ne Mixeda 7.7% unilateral
DVT
C
Mixeda 13.3% bilateral
DVT
1, 3, and 9
onths.
Anticoagulation 18.8% B
1 day and 4
eeks
LMWH 7days, then
half dose 3 weeks
2.9% B
ne Anticoagulation,
92.5-94.4%
Muscular C-
DVT: 1.5%
Axial C-DVT:
1.4%
C
ombosis; LMWH, low-molecular-weight heparin; VKA, vitamin K agonist.
ial period 2004-2006.Pre
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patient found to have an asymptomatic PE at presentation, its
clinical significance remains controversial, and routine pulmo-
nary scans in all asymptomatic patients is probably not eco-
nomically feasible.
Recurrence in C-DVT is lower than DVT of the
thigh.23,26 Recurrence may be reduced by anticoagula-
tion25 with treatment up to 12 weeks, particularly in those
with two or more calf vein thrombi,27 or risk factors such as
malignancy, permanent risk factors, or idiopathic causes.26
The studies of PTS showed that patients with C-DVT
fared better over time with fewer symptoms of PTS than
those with proximal DVT.33,52 At 1 year, based on a
longitudinal study by Meissner,33 23% of C-DVT were
symptomatic with pain and swelling. At 3 to 4 years,
McLafferty51 reported few with significant venous symp-
toms, and at 5 years, one out of 10 showedCEAPClass 4 to
6 findings according to Asbeutah and colleagues.53 Both
McLafferty51 and Asbeutah53 reported approximately one-
third with reflux of the affected limb and unexpectedly high
incidence of reflux in unaffected venous segments50 and
Table VI. Postthrombotic syndrome
Author
No. of
patients/limbs
Length of
follow-up
Diagnostic test fo
PTS
Lawrence and
Kakkar
(1980)50
58 2 years Foot volumetry
Kakkar and
Lawrence
(1985)29
(98) 2 years Foot volumetry
Meissner
(1998)33
72 (including
35
controls)
1 year DUS
McLafferty
(1998)51
71 (including
34
controls)
3.4 years DUS
Masuda
(1998)35
49 (including
26
controls)
3 years DUS
Saarinen
(2002)52
62 6-10
years
None
Asbeutah
(2004)53
76 (including
48
controls)
5 years DUS
Rosfors
(2010)54b
46 5 years DUS and
plethysmograph
C-DVT, Calf deep vein thrombosis; DUS, duplex ultrasound; DVT, deep ve
aLevel of reflux not specified.
bAll asymptomatic C-DVT.unaffected limbs,52 which suggests underlying valvular dys- aunction may have preceded the DVT, possibly predispos-
ng them to clotting, or the DVT may be the result of a
ystemic valvular problem.Of note is that venous ulceration
as not commonly reported by 5-year follow-up stud-
es.53,54 If patients are asymptomatic, their prognosis at 5
ears may be even better than their symptomatic counter-
arts with only 4% mild PTS findings.
How do clot propagation, PE, recurrence, and PTS
nterrelate? Based on this review, propagation of C-DVT
ith no anticoagulation did not appear to lead to a large
umber of PE despite a propagation rate of 2% to 15% to
he popliteal or higher, which is likely the result of close
uplex surveillance, prompt recognition of propagation,
nd appropriate anticoagulation. What is concerning is that
ot all PE were preceded by propagation, demonstrating
ow duplex surveillance and selective monitoring may not
e protective in all cases. Such a risk for PE during surveil-
ance would need to be considered when determining best
anagement. Although this review did not show it, recur-
ence may contribute to development of valvular reflux64
% Abnormal test for
PTS Clinical findings Rating
Normal 45%, mild-
moderate 41%,
severe 14%
Not reported C
Normal 40%, mild-
moderate 41%,
severe 19%
Asymptomatic or minimal
symptoms 78%,
moderate 16%, severe
5%.
C
Reflux in 24% C-DVT
in calf veins, 0 in
controls, P  .002
Symptomatic in C-DVT
limbs 23%, in controls
9% at 1 year
B
Reflux in 26% C-DVT
limbsa, 6% controls,
P  .05
CEAP Class 1-6 in 38%,
all “Mild except one
patient.”
B
Reflux 39%: 9% in
original C-DVT
vein, 30% in vein not
involved with DVT,
no difference from
controls.
CEAP Class 0 in 74%,
Class 2 in 8.7%, Class
3-4 in 17.4%, Class 5-6
in 0.
C
None Asymptomatic 37%,
moderate 58%, severe
5%
C
Reflux in 36% C-
DVTa, 52% in
controls primarily
superficial veins 64%.
CEAP Class 0 in 46%,
Class 1-3 in 43%, Class
4-6 in 11%
B
Reflux 50% in distal
veins; deep vein
reflux more common
in two or more calf
veins than single,
P  .05
Villalta score 7% score
5 (indicative of PTS),
all classified as mild.
B
ombosis; PTS, postthrombotic syndrome.r
y
in thrnd possibly greater risk for PTS.
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Volume 55, Number 2 Masuda et al 559This review has major limitations inherent in any sys-
tematic review. Unfortunately, a meta-analysis was not
possible because of lack of sufficient well-designed compar-
ative trials aimed at addressing the question posed. Further,
studies could have been missed that were not included in
our search under our keywords or those not written in
English, validity of the grading system has not been previ-
ously tested, sample sizes were small even in the RCTs, and
bias can never be totally eliminated. We found significantly
more studies reporting results of anticoagulation than ob-
servation, which may lead to sampling error, and may not
represent actual clinical practice.
The current body of literature does not appear to
support a universal recommendation for treating C-DVT.
Based on the grading system by Guyatt et al,65 there is
Grade IIB evidence for managing with either anticoagula-
tion for an undetermined duration or observation with
elastic support and surveillance imaging studies. A third
option of no specific therapy other than support stockings
and ignoring the calf is inappropriate given the established
reality of clot propagation, clot recurrence, and small but
not insignificant risk of PE. In considering the first two
options, well-designed and adequately powered studies are
necessary to prove which alternative is better for any given
clinical setting, and also which would be preferred given
patient risk factors for ongoing complications of venous
thromboembolism. Guidelines based on the current evi-
dence must allow for these two choices.
The authors would like to thank Mrs Fran Smith for
tireless effort in gathering the papers for this article.
AUTHOR CONTRIBUTIONS
Conception and design: EM, FL
Analysis and interpretation: EM, RK, CM, FL, OG, QH
Data collection: EM, FL
Writing the article: EM, RK
Critical revision of the article: EM, RK, CM, OG
Final approval of the article: EM, RK, CM, FL, OG
Statistical analysis: QH
Obtained funding: Not applicable
Overall responsibility: EM
REFERENCES
1. Kearon C, Kahn SR, Agnelli G, Goldhaber S, RaskobGE, Comerota AJ;
American College of Chest Physicians. Antithrombotic therapy for
venous thromboembolic disease: American College of Chest Physicians
Evidence-based Clinical Practice Guidelines (8th edition). Chest 2008;
133(6 Suppl):454S-545S.
2. Philbrick JT, Becker DM. Calf deep venous thrombosis. A wolf in
sheep’s clothing? Arch Intern Med 1988;148:2131-8.
3. Browse NL, Clemenson G, Thomas ML. Is the postphlebitic leg always
postphlebitic? Relation between phlebographic appearances of deep-
vein thrombosis and late sequelae. Br Med J 1980;281:1167-70.
4. Schulman S, Granqvist S, Juhlin-Dannfelt A, Lockner D. Long-term
sequelae of calf vein thrombosis treated with heparin or low-dose
streptokinase. Acta Med Scand 1986;219:349-57.
5. Doouss TW. The clinical significance of venous thrombosis of the calf.
Br J Surg 1976;63:377-8.6. Holmgren K, Andersson G, Fagrell B, Johnsson H, Ljungberg B,
Nilsson E, et al. One-month versus six-month therapy with oral antico-agulants after symptomatic deep vein thrombosis. Acta Med Scand
1985;218:279-84.
7. Schulman S, Lockner D, Juhlin-Dannfelt A. The duration of oral
anticoagulation after deep vein thrombosis. A randomized study. Acta
Med Scand 1985;217:547-52.
8. Lindhagen A, Bergqvist A, Bergqvist D, Hallbook T. Late venous
function in the leg after deep venous thrombosis occurring in relation to
pregnancy. Br J Obst Gyn 1986;93:348-52.
9. Lindner DJ, Edwards JM, Phinney ES, Taylor LM, Porter JM. Long-
term hemodynamic and clinical sequelae of lower extremity deep vein
thrombosis. J Vasc Surg 1986;4:436-42.
0. CheungHY, ChungCC, Yau KK, SiuWT,Wong SK, Chiu E, et al. Risk
of deep vein thrombosis following laparoscopic rectosigmoid cancer
resection in Chinese patients. Asian J Surg 2008;31:63-8.
1. Labropoulos N, Waggoner T, Sammis W, Samali S, Pappas PJ. The
effect of venous thrombus location and extent on the development of
post-thrombotic signs and symptoms. J Vasc Surg 2008;48:407-12.
2. Palareti G, Agnelli G, Imberti D,MoiaM, AgenoW, Pistelli R, et al. Do
Italian vascular centers look for isolated calf deep vein thrombosis?
Analysis of isolated calf deep vein thromboses included in the “Master”
Registry. Int Angiol 2008;27:482-8.
3. Palareti G, Agnelli G, Imberti D, Moia M, Ageno W, Pistelli R, et al. A
commentary: to screen for calf DVT or not to screen? The highly
variable practice among Italian centers highlights this important and
still unresolved clinical option. Results from the Italian MASTER
registry. Thromb Haemost 2008;99:241-4.
4. Bernardi E, Camporese G, Büller HR, Siragusa S, Imberti D, et al. Serial
2-point ultrasonography plus D-dimer vs whole-leg color-coded Dopp-
ler ultrasonography for diagnosing suspected symptomatic deep vein
thrombosis: a randomized controlled trial. JAMA 2008;300:1653-9.
5. Kearon C, Ginsberg JS, AndersonDR, KovacsMJ,Wells P, Julian JA, et
al. Comparison of 1 month with 3 months of anticoagulation for a first
episode of venous thromboembolism associated with a transient risk
factor. J Thromb Haemost 2004;2:743-9.
6. Lindhagen A, Bergqvist D, Hallböök T, Efsing HO. Venous function
five to eight years after clinically suspected deep venous thrombosis.
Acta Med Scand 1985;217:389-95.
7. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lärfars G, Nicol P,
et al. A comparison of six weeks with six months of oral anticoagulant
therapy after a first episode of venous thromboembolism. Duration of
Anticoagulation Trial Study Group. N Engl J Med 1995;332:1661-5.
8. Moreno-Cabral R, Kistner RL, Nordyke RA. Importance of calf vein
thrombophlebitis. Surgery 1976;80:735-42.
9. Ohgi S, Tachibana M, Ikebuchi M, Kanaoka Y, Maeda T, Mori T.
Pulmonary embolism in patients with isolated soleal vein thrombosis.
Angiology 1998;49:759-64.
0. Righini M, Le Gal G, Aujesky D, Roy PM, Sanchez O, Verschuren F, et
al. Complete venous ultrasound in outpatients with suspected pulmo-
nary embolism. J Thromb Haemost 2009;7:406-12.
1. Passman MA, Moneta GL, Taylor LM, Edwards JM, Yeager RA,
McConnell DB, et al. Pulmonary embolism is associated with the
combination of isolated calf vein thrombosis and respiratory symptoms.
J Vasc Surg 1997;25:39-45.
2. Lautz TB, Abbas F, Novis-Walsh SJ, Chow C, Amaranto DJ, Wang E,
et al. Isolated gastrocnemius and soleal vein thrombosis. Ann Surg
2009;251:735-42.
3. Hull R, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, et al.
Warfarin sodium versus low-dose heparin in the long-term treatment of
venous thrombosis. N Engl J Med 1979;301:855-8.
4. Bentley PG, Kakkar VV, ScullyMF,MacGregor IR,Webb P, Chan P, et
al. An objective study of alternative methods of heparin administration.
Thromb Res 1980;18:177-87.
5. Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U.
Need for long-term anticoagulant treatment in symptomatic calf-vein
thrombosis. Lancet 1985;2:515-8.
6. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S,
Durieu I, et al. Comparison of 3 and 6 months of oral anticoagulant
therapy after a first episode of proximal deep vein thrombosis or
pulmonary embolism and comparison of 6 and 12 weeks of therapy after
isolated calf deep vein thrombosis. Circulation 2001;103:2453-60.
55
5
5
5
5
5
5
5
5
6
6
6
6
6
6
S
A
S
a
t
i
h
S
p
JOURNAL OF VASCULAR SURGERY
February 2012560 Masuda et al27. Ferrara F, Meli F, Amato C, Cospite V, Raimondi F, et al. Optimal
duration of treatment in surgical patients with calf venous thrombosis
involving one or more veins. Angiology 2006;57:418-23.
28. Schwarz T, Buschmann L, Beyer J, Halbritter K, Rastan A, Schellong S.
Therapy of isolated calf muscle vein thrombosis: a randomized, con-
trolled study. J Vasc Surg 2010;52:1246-50.
29. Kakkar VV, Lawrence D. Hemodynamic and clinical assessment after
therapy for acute deep vein thrombosis. A prospective study. Am J Surg
1985;150:54-63.
30. Lohr JM, Kerr TM, Lutter KS, Cranley RD, Spirtoff K, Cranley JJ.
Lower extremity calf thrombosis: to treat or not to treat? J Vasc Surg
1991;14:618-23.
31. Solis MM, Ranval TJ, Nix ML, Eidt JF, Nelson CL, Ferris EJ, et al. Is
anticoagulation indicated for asymptomatic postoperative calf vein
thrombosis? J Vasc Surg 1992;16:414-9.
32. Lohr JM, James KV, Deshmukh RM, Hasselfeld KA. Allastair B.
Karmody Award. Calf vein thrombi are not a benign finding. Am J Surg
1995;170:86-90.
33. Meissner MH, Caps MT, Bergelin RO, Manzo RA, Strandness DE.
Early outcome after isolated calf vein thrombosis. J Vasc Surg 1997;26:
749-56.
34. O’Shaughnessy AM, Fitzgerald DE. The value of duplex ultrasound in
the follow-up of acute calf vein thrombosis. Int Angiol 1997;16:142-6.
35. Masuda EM, Kessler DM, Kistner RL, Eklof B, Sato DT. The natural
history of calf vein thrombosis: lysis of thrombi and development of
reflux. J Vasc Surg 1998;28:67-74.
36. Kazmers A, Groehn H, Meeker C. Acute calf vein thrombosis: out-
comes and implications. Am Surg 1999;65:1124-8.
37. Schwarz T, Schmidt B, Beyer J, Schellong SM. Therapy of isolated calf
muscle vein thrombosis with low-molecular-weight heparin. Blood
Coagul Fibrinolysis 2001;12:597-99.
38. Labropoulos N, Kang SS, Mansour MA, Giannoukas AD, Moutzouros
V, Baker WH. Early thrombus remodelling of isolated calf deep vein
thrombosis. Eur J Vasc Endovasc Surg 2002;23:344-48.
39. MacDonald PS, Kahn SR, Miller N, Obrand D. Short-term natural
history of isolated gastrocnemius and soleal vein thrombosis. J Vasc
Surg 2003;37:523-7.
40. Wang CJ, Wang JW, Weng LH, Huang CC, Yu PC. Clinical signifi-
cance of muscular deep-vein thrombosis after total knee arthroplasty.
Chang Gung Med J 2007;30:41-6.
41. Parisi R, Visonà A, Camporese G, Verlato F, Lessiani G, Antignani PL,
et al. Isolated distal deep vein thrombosis: efficacy and safety of a
protocol of treatment. Treatment of Isolated Calf Thrombosis (TICT)
Study. Int Angiol 2009;28:68-72.
42. Palareti G, Cosmi B, Lessiani G, Rodorigo G, Guazzaloca G, Brusi C, et
al. Evolution of untreated calf deep-vein thrombosis in high risk symp-
tomatic outpatients: the blind, prospective CALTHRO study. Thromb
Haemost 2010;104:1063-70.
43. Partsch H. Therapy of deep vein thrombosis with low molecular weight
heparin, leg compression and immediate ambulation. VASA 2001;30:
195-204.
44. Wang C, Wang J, Weng L, Hsu C, Lo C. Outcome of calf deep-vein
thrombosis after total knee arthroplasty. J Bone Joint Surg (Br) 2003;
85-B:841-4.
45. Gillet JL, Perrin MR, Allaert FA. Short-term and mid-term outcome of
isolated symptomatic muscular calf vein thrombosis. J Vasc Surg 2007;
46:513-19.
46. Astermark J, Bjorgell O, Linden E, Lethagen S, Nilsson P, Berntorp E.
Low recurrence rate after deep calf-vein thrombosis with 6 weeks of oral
anticoagulation. J Int Med 1998;244:79-82.
47. Seinturier C, Bosson JL, ColonnaM, Imbert B, Carpentier PH. Site and
clinical outcome of deep vein thrombosis of the lower limbs: an epide-
miological study. J Thromb Haemost 2005;3:1362-7.
48. Galanaud J, SevestreM,Genty C, Laroche J, Zizka V,Quere I, et al, and
the OPTIMEV SFMV investigators. Comparison of the clinical history
of symptomatic isolated muscular calf vein thrombosis versus deep calf
vein thrombosis. J Vasc Surg 2010;52:932-8.49. Galanaud JP, Sevestre-Pietri MA, Bosson JL, Laroche JP, Righini M,
Brisot D, et al. Comparative study on risk factors and early outcome of usymptomatic distal versus proximal deep vein thrombosis: results from
the OPTIMEV study. Thromb Haemost 2009;102:493-500.
0. Lawrence D, Kakkar VV. Post-phlebitic syndrome-a functional assess-
ment. Br J Surg 1980;67:686-9.
1. McLafferty RB, Moneta GL, Passman MA, Brant BM, Taylor LM Jr,
Porter JM. Late clinical and hemodynamic sequelae of isolated calf vein
thrombosis. J Vasc Surg 1998;27:50-6.
2. Saarinen J, Domonyi K, Zeitlin R, Salenius JP. Post-thrombotic symp-
toms after an isolated calf deep venous thrombosis. J Cardiovasc Surg
2002;43:687-91.
3. Asbeutah AM, Riha AZ, Cameron JD,McGrath BP. Five-year outcome
study of deep vein thrombosis in the lower limbs. J Vasc Surg 2004;40:
1184-9.
4. Rosfors S, Persson LM, Larfars G, Lapidus LJ. A follow-up study of the
fate of small asymptomatic deep venous thromboses. Thrombo J 2010;
8:4.
5. Markel A, Manzo RA, Bergelin RO, Strandness DE. Pattern and
distribution of thrombi in acute venous thrombosis. Arch Surg 1992;
127:305-9.
6. East AT, Wakefield TW. What is the optimal duration of treatment for
DVT? An update on evidence-based medicine of treatment for DVT.
Semin Vasc Surg 2010;23:182-91.
7. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, et al.
D-dimer testing to determine the duration of anticoagulation therapy.
N Engl J Med 2006;355:1780-9.
8. Prandoni P, Prins MH, Lensing AW, Ghirarduzzi A, AgenoW, Imberti
D, et al. Residual thrombosis on ultrasonography to guide the duration
of anticoagulation in patients with deep venous thrombosis: a random-
ized trial. Ann Intern Med 2009;150:577-85.
9. Browse NL, Thomas ML. Source of non-lethal pulmonary emboli.
Lancet 1974;1:258-65.
0. Bartter T, Hollingsworth HM, Irwin RS, Bianco JA, Frid DJ, Dalen JE.
Pulmonary embolism from a venous thrombus located below the knee.
Arch Intern Med 1987;147:373-75.
1. Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, et al.
Continuous intravenous heparin compared with intermittent subcuta-
neous heparin in the initial treatment of proximal-vein thrombosis.
N Engl J Med 1986;315:1109-14.
2. Brandjes DP, Heijboer H, Büller HR, de Rijk M, Jagt H, ten Cate JW.
Acenocoumarol and heparin compared with acenocoumarol alone in
the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;
327:1485-9.
3. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The
weight-based heparin dosing nomogram compared with a “standard
care” nomogram. A randomized controlled trial. Ann Intern Med
1993;119:874-81.
4. Meissner MH, Caps MT, Bergelin RO, Manzo RA, Strandness DE Jr.
Propagation, rethrombosis and new thrombus formation after acute
deep venous thrombosis. J Vasc Surg 1995;22:558-67.
5. Guyatt GH, CookDJ, Jaeschke R, Pauker SG, SchunemannHJ. Grades
of Recommendation for Antithrombotic Agents. Chest 2008;133:
123S-131S.
ubmitted Aug 10, 2010; accepted May 31, 2011.
PPENDIX
tandard 1: Comparative trials
Comparative studies examining outcomes of different man-
gement strategieswouldprovide themostmeaningful datawith
he strongest evidencederived fromrandomized studies contain-
ng controls. Studies that had no controls, either internal or
istoric, would not have satisfied this standard.
tandard 2: Unbiased recruitment of patients and
atient assembly
Papers were graded as to whether the recruitment was
nbiased or consecutive. This standard would be met if the
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Volume 55, Number 2 Masuda et al 561study was consecutive or if a detailed report of exclusions
was described. To better understand the natural history of
C-DVT, the study group at inception should be identified
early in the disease process or at a uniform point in the
disease process.
Standard 3: Adequate description of the group,
demographics, risk factors
Numerous risk factors and demographics could influ-
ence outcome of DVT propagation; therefore, characteris-
tics of each group should be specified, including demo-
graphics (age, gender) and risk factors for DVT such as
cancer, recent surgery, or previous DVT, history of throm-
bophilia, provoked or reversible risk factors, or unprovoked
idiopathic circumstances.
Standard 4: Adequate surveillance with objective
testing
To satisfy this standard, determination of clot propaga-
tion required repeat venous leg studies and PE during
surveillance-required repeat, predetermined pulmonary
studies such as V/Q studies or computed tomography
(CT) angiograms of the chest for both asymptomatic and
symptomatic patients.
Standard 5: Adequate testing for DVT and
pulmonary emboli
To identify C-DVT limited to the calf veins not involv-
ing the popliteal vein, objective testing by either duplex
ultrasound scanning, compression ultrasound, contrast
venography, or radionuclide leg studies validated by venog-
raphy was required.
For reporting PE at presentation and PE during sur-
veillance, diagnosis must be confirmed by V/Q scanning iith perfusion and ventilation examinations, or CT angio-
ram of the chest. Clinical diagnosis of PE would not be
onsidered meeting this standard.
For postthrombotic syndrome, objective testing for ana-
omic or physiological abnormalities such as reflux and/or
bstruction was needed to determine presence of PTS.
tandard 6: Treatment and dose of anticoagulation
Details of the type of anticoagulant and dosing
hould be specified in studies examining cases with anti-
oagulation.
tandard 7: Adequate follow-up
For propagation of DVT, a minimum of 2 weeks’
ollow-up with surveillance imaging was required to meet
he standard. For PE during surveillance and recurrence, a
inimum for duration of follow-up was not set because the
ength of follow-up even if short was felt to be of value. For
ating postthrombotic syndrome, the length of follow-up
as critical, and therefore a minimum follow-up of 1 year
as required to satisfy this standard.
tandard 8: Identifying PE at presentation
In order to accurately assess the incidence of PE during
anagement of C-DVT, those presenting with PE must be
dentified early at the time of entry into the study and must
e distinguished from PE during surveillance.
tandard 9: Bleeding
To more fully assess the risk of anticoagulation in
reatment, we required that details of bleeding be reported
n those studies where anticoagulation was used.
